Generic competition and market exclusivity periods in pharmaceuticals

Published

Journal Article

In this paper we examine generic competition and market exclusivity periods for pharmaceuticals experiencing their initial generic entry between 1995 and 2005. We find that generic competition has increased over several dimensions. First, an increasing number of drugs are subject to generic entry, including drugs with relatively modest annual average sales. Second, drugs with larger sales attract more generic entrants and have shorter market exclusivity periods than smaller selling drugs. Third, blockbuster drugs with annual sales in excess of $1 billion have experienced significant decreases in their market exclusivity periods in recent years. We also find that Hatch-Waxman Act patent challenges have negatively affected market exclusivity periods over the 1995 to 2005 period. Copyright © 2007 John Wiley & Sons, Ltd.

Full Text

Duke Authors

Cited Authors

  • Grabowski, HG; Kyle, M

Published Date

  • June 1, 2007

Published In

Volume / Issue

  • 28 / 4-5

Start / End Page

  • 491 - 502

Electronic International Standard Serial Number (EISSN)

  • 1099-1468

International Standard Serial Number (ISSN)

  • 0143-6570

Digital Object Identifier (DOI)

  • 10.1002/mde.1356

Citation Source

  • Scopus